Subscribe to Newsletter
Diagnostics Companion diagnostics

Precision Medicine Pioneers

sponsored by Thermo Fisher Scientific

As Thermo Fisher Scientific’s Oncomine Dx in-house NGS solutions go from strength to strength, so strengthens their vision of worldwide availability of ultra-rapid NGS-sequencing-based solutions.

In this interview with The Pathologist, Luca Quagliata reflects on Thermo Fisher Scientific’s history in precision medicine, the priorities driving their current strategy, and future predictions for the field.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Luca Quagliata

Vice-President, Medical Affairs, Clinical Next-Generation Sequencing Division, Genetic Sciences Group, Thermo Fisher Scientific

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine